Recruiting

Telehealth Opioid Education

Sponsor:

Fred Hutchinson Cancer Center

Code:

NCT07737314

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Survey Administration

Electronic Health Record Review

Study Details

Brief summary:

This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.

Conditions

Hematopoietic and Lymphatic System Neoplasm

Malignant Solid Neoplasm

Study ID

NCT07737314

Start date

Nov 3, 2026

Status verified date

Jul, 2026

Completion date

Aug 31, 2027

Anticipated

Primary completion date

Jul 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
  • A cancer diagnosis
  • Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
  • Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
  • Ability to understand and willingness to agree to an electronic consent document
  • Enrolled in MyChart and ability to participate in a telehealth video visit

Exclusion Criteria:

  • Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Supportive care (pharmacist-led opioid education session)

Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.

Interventions

Survey Administration

Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability

Electronic Health Record Review

Ancillary studies

Primary outcome measure

  • Percentage of referred patients who attend pharmacist education session (Feasibility) [ Time Frame: Up to 6 months ]
  • Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire [ Time Frame: Up to 1 month post-session ]

Central Contacts and Locations

Central contacts

Sheri Ballard

206-667-4222sballard@fredhutch.org

Locations

Fred Hutch/University of Washington Cancer Consortium

Recruiting

Seattle, Washington, United States, 98109

Contacts

Sheri Ballard

206-667-4222sballard@fredhutch.org

Principal Investigator:

Nicole Dussault, MD, MS

More Information

Sponsor

Fred Hutchinson Cancer Center

Last update posted

Nov 6, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-07. This information was provided to ClinicalTrials.gov by Fred Hutchinson Cancer Center on 2026-11-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.